Telix Pharmaceuticals (TLX) Stock Statistics & Valuation Metrics

Telix Pharmaceuticals has a market cap or net worth of $8.62B. The enterprise value is ―.

Telix Pharmaceuticals has 338,109,040 shares outstanding. The number of shares has decreased by -2.65% in one year.

Telix Pharmaceuticals’s return on equity (ROE) is ― and return on invested capital (ROIC) is ―.

The current PE Ratio of Telix Pharmaceuticals is ―. Telix Pharmaceuticals’s PEG ratio is ―.

In the last 12 months, Telix Pharmaceuticals had revenue of 496.66M and earned 5.21M in profits. Earnings per share was 0.02.

In the last 12 months, operating cash flow was 44.23M and capital expenditures -21.48M, giving a free cash flow of 22.75M billion.

Telix Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Telix Pharmaceuticals upcoming earnings date is Aug 21, 2025, TBA Not Confirmed.

Telix Pharmaceuticals as a current ratio of ―, with Debt / Equity ratio of ―

In the past 12 months, Telix Pharmaceuticals has paid -2.12M in taxes.

Telix Pharmaceuticals EV to EBITDA ratio is ―, with an EV/FCF ratio of ―.

Telix Pharmaceuticals has $118.84M in cash and marketable securities with AU$22.14M in debt, giving a net cash position of -$96.69M billion.

Gross margin is ―, with operating margin of ―, and net profit margin of ―.

The average price target for Telix Pharmaceuticals is $35.34, which is 11.43% higher than the current price. The consensus rating is Strong Buy